NCT02956109 - Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 16, 2016

Primary Completion Date

December 22, 2016

Study Completion Date

March 17, 2017

Conditions

Pharmacokinetics

Interventions

DRUG

Finerenone (BAY94-8862): 1 0mg tablet

10 mg finerenone immediate-release tablet; single dose in the fasting condition

DRUG

Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets

5 x 0.25 mg (1.25 mg) oro-dispersible tablets; single dose in the fasting condition

DRUG

Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet

1.25 mg finerenone oro-dispersible tablets; single dose in the fasting condition or in the fed condition

Trial Locations (1)

Mönchengladbach